Hormonal
Retatrutide increases the incidence of adverse events, particularly nausea, vomiting, and decreased appetite, in a dose-dependent manner compared to placebo.
While effective, retatrutide causes more side effects than placebo, including nausea, vomiting, and constipation. These side effects increase with higher doses (8mg and 12mg). Patients should be prepared for these potential issues, which may affect adherence.
Compared to placebo, patients receiving retatrutide experienced higher occurrences of nausea, vomiting, decreased appetite, diarrhea, and constipation.
Why this rating
Based on the same 3 RCTs; safety data was consistent across doses.
Source
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Alaa Abdrabou Abouelmagd et al. · Baylor University Medical Center Proceedings · 2025
DOI 10.1080/08998280.2025.2456441
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →